CLINICAL TRIALS PROFILE FOR CEFEPIME HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for cefepime hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00020865 ↗ | Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia | Unknown status | National Cancer Institute (NCI) | Phase 3 | 2001-09-01 | RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer. |
| NCT00020865 ↗ | Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia | Unknown status | Jonsson Comprehensive Cancer Center | Phase 3 | 2001-09-01 | RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer. |
| NCT00044759 ↗ | Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 1969-12-31 | To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma. |
| NCT00137787 ↗ | Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases | Completed | Bayer | Phase 3 | 2005-04-01 | The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases. |
| NCT00137787 ↗ | Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases | Completed | Center for Supporting Hematology-Oncology Trials | Phase 3 | 2005-04-01 | The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for cefepime hydrochloride
Condition Name
Clinical Trial Locations for cefepime hydrochloride
Trials by Country
Clinical Trial Progress for cefepime hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for cefepime hydrochloride
Sponsor Name
